Conference Coverage

IL-6 nanobody vobarilizumab advances despite equivocal phase II data


 

AT EULAR 2017

– Despite failing its phase II primary endpoint, the single-domain antibody vobarilizumab, being developed for rheumatoid arthritis, will advance to phase III studies.

A robust placebo response obscured the strength of clinical response to vobarilizumab, a nanobody that blocks the soluble interleukin-6 receptor, Thomas Dorner, MD, said at the European Congress of Rheumatology. But by 24 weeks of treatment, vobarilizumab effected a deep, sustained response in up to half of patients with rheumatoid arthritis who responded inadequately to methotrexate.

Word cloud of rheumatoid arthritis copyright kgtoh/Thinkstock
“Overall, we think these results indicate a strong potential of disease-modifying activity, supporting treat-to-target management of RA,” said Dr. Dorner of Charite University Hospitals Berlin, Germany. He said regional differences in treatment groups contributed to the strong placebo response. “This trial included subjects from regions with very little or no access to biologics. This, we think, created a very strong placebo response.”

The safety profile was encouraging, Dr. Dorner said, with just one case of gastrointestinal perforation. These events have been a problem in some IL-6 blockade studies; the protein stimulates repair of the intestinal epithelium and blocking it leaves the tissue vulnerable to injury. The single case in this trial occurred 17 days after the patient withdrew from the study for other reasons, so it was not considered to be related to the study medication, Dr. Dorner said.

Vobarilizumab is composed of two heavy chains, lacking the two light-chain arms of a full antibody. It is minuscule – just 10% of the molecular weight of a conventional antibody. One chain targets human serum albumin and is designed to prolong the molecule’s half-life by up to 14 days; the other chain targets the soluble IL-6 receptor.

The phase IIb study comprised 345 patients with active RA despite treatment with methotrexate (mean dose 16 mg/week). While staying on their methotrexate, they were equally assigned to five treatment groups: placebo or vobarilizumab at 75 mg every 4 weeks; 150 mg every 4 weeks; 150 mg every 2 weeks; or 225 mg every 2 weeks.

The primary endpoint was the difference in ACR20 response at week 12 between placebo and the four dosing groups. While the majority of patients taking vobarilizumab met that endpoint, the percentages did not significantly differ from each other, nor from placebo. ACR20 was met by 62% of the placebo group and 81%-72% of the vobarilizumab groups. ACR50 was met by 28% of the placebo group and 45%-29% of the vobarilizumab groups and ACR70 by 9% of the placebo group and 21%-14% of the vobarilizumab groups.

However, Dr. Dorner said, response in the placebo group tended to tail off as the study progressed, while staying significantly stronger in the higher-dose vobarilizumab groups. By week 24, 16% of the placebo group still had an ACR50 – significantly less than in the vobarilizumab 150 mg/2 weeks and 225 mg/2 weeks groups (31%, 39%, respectively).

On a measure of remission that combined C-reactive protein of less than 2.6 mg/L and low disease activity, vobarilizumab looked much better at week 24. At that point, 16% of placebo patients met the endpoint, compared to 39% of the 150 mg/4 weeks and 150 mg/2 weeks vobarilizumab groups, and 51% of the 225 mg/2 weeks group.

Adverse events occurred in 36% of placebo patients and about 44% of vobarilizumab patients and did not show any dose-response relationship. About 38% of these were considered treatment related; 7% of the cohort withdrew due to an adverse event. There were seven serious infections among those taking vobarilizumab (three pneumonia, and one each herpes zoster, ear infection, staphylococcus sepsis, and bacterial arthritis). One patient died of a myocardial infarction, but she had experienced a previous heart attack and undergone percutaneous coronary intervention. The single gastrointestinal perforation occurred in a woman taking the highest dose of vobarilizumab, more than 2 weeks after she stopped taking it.

Vobarilizumab will continue into a phase III study, according to the Ablynx website. The company is seeking an industry partner. AbbVie had an option to license vobarilizumab, but declined last fall on the mixed results of Ablynx’s phase II studies.

On Twitter @Alz_gal

Recommended Reading

Study sheds light on pregnancy outcomes following ocrelizumab treatment
MDedge Rheumatology
VIDEO: No cancer risk found from biological DMARDs
MDedge Rheumatology
Prophylaxis prevents PCP in rheumatic disease patients
MDedge Rheumatology
Studies provide insight into link between cancer immunotherapy and autoimmune disease
MDedge Rheumatology
VIDEO: Adding ultrasound to treat to target doesn’t improve RA remission outcomes
MDedge Rheumatology
VIDEO: Rheumatology biosimilars gain U.S. momentum
MDedge Rheumatology
VIDEO: Childhood second-hand smoke boosts RA incidence
MDedge Rheumatology
Safety data review finds no increased risk of infection from abatacept
MDedge Rheumatology
Biologics, TNF-inhibitors confer no excess cancer risks upon RA patients
MDedge Rheumatology
Biosimilar immunogenicity studies produce no surprises
MDedge Rheumatology